Evidence map›Paper›PMID 23064977›Full record

ArticleJournal of clinical immunology2013

Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells.

Nuno Costa, Ana E Pires, Ana M Gabriel, Luiz F Goulart, Clara Pereira, Bárbara Leal, Ana C Queiros, Wahiba Chaara, Maria F Moraes-Fontes, Carlos Vasconcelos and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nuno CostaInstituto Gulbenkian de Ciência, Apartado 14, 2781-901, Oeiras, Portugal.
Ana E Pires
Ana M Gabriel
Luiz F Goulart
Clara Pereira
Bárbara Leal
Ana C Queiros
Wahiba Chaara
Maria F Moraes-Fontes
Carlos Vasconcelos
Carlos Ferreira
Jorge Martins
Marina Bastos
Maria J Santos
Maria A Pereira
Berta Martins
Margarida Lima
Cristina João
Adrien Six
Jocelyne Demengeot
Constantin Fesel

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIntravenous IgG (ivIg) is a therapeutic alternative for lupus erythematosus, the mechanism of which remains to be fully understood. Here we investigated whether ivIg affects two established sub-phenotypes of SLE, namely relative oligoclonality of circulating T-cells and reduced activity of CD4 + Foxp3+ regulatory T-cells (Tregs) reflected by lower CD25 surface density.

methodsWe conducted a longitudinal study of 15 lupus patients (14 with SLE and one with discoid LE) treated with ivIg in cycles of 2-6 consecutive monthly infusions. Among these 15 patients, 10 responded to ivIg therapy with clear clinical improvement. We characterized Tregs and determined TCR spectratypes of four Vβ families with reported oligoclonality. Cell counts, cytometry and TCR spectratypes were obtained from peripheral blood at various time points before, during and after ivIg treatment. T-cell oligoclonality was assessed as Vβ-familywise repertoire perturbation, calculated for each patient in respect to an individual reference profile averaged over all available time points.

resultsFor 11 out of 15 patients, average Vβ1/Vβ2/Vβ11/Vβ14 repertoires were less perturbed under than outside ivIg therapy. The four exceptions with relatively increased average perturbation during ivIg therapy included three patients who failed to respond clinically to an ivIg therapy cycle. Patients' Treg CD25 surface density (cytometric MFI) was clearly reduced when compared to healthy controls, but not obviously influenced by ivIg. However, patients' average Treg CD25 MFI was found negatively correlated with both Vβ11 and Vβ14 perturbations measured under ivIg therapy.

conclusionsThis indicates a role of active Tregs in the therapeutic effect of ivIg.

Indexed as

Immunoglobulins, IntravenousAdultForkhead Transcription FactorsHumansInterleukin-2 Receptor alpha SubunitLongitudinal StudiesLupus Erythematosus, SystemicMiddle AgedReceptors, Antigen, T-Cell, alpha-betaT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsYoung AdultForkhead Transcription FactorsFOXP3 protein, humanImmunoglobulins, IntravenousInterleukin-2 Receptor alpha SubunitReceptors, Antigen, T-Cell, alpha-beta

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.